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Abstract: Liposomal amphotericin B is a “true” liposomal formulation of amphotericin B 
with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum 
polyene is well tolerated and effective against most invasive fungal infections. In view of the 
current limitations on diagnostic capability of invasive fungal infections, most clinicians are often 
compelled to use antifungal drugs in an empiric manner; liposomal amphotericin B continues 
to play an important role in the empiric management of invasive fungal infections, despite the 
recent availability of several other drugs in the azole and echinocandin classes.
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Introduction
Invasive fungal infections (IFIs) have become a leading cause of morbidity and mortal-
ity among immunocompromised patients.1 The incidence of IFIs in these patient popula-
tions has increased dramatically over the past three decades. The most common fungal 
pathogens include Candida albicans and Aspergillus fumigatus and   cryptococcus. 
However, uncommon pathogens such as non-albicans Candida spp, opportunistic 
yeast-like fungi (eg, Trichosporon and Rhodotorula spp), non-fumigatus Aspergillus 
spp, Mucorales and hyaline molds (eg, Fusarium and Scedosporium spp) are now 
emerging as not-so-uncommon opportunistic pathogens.2,3 Etiologic identification 
of fungal pathogens is frequently difficult, particularly in compromised hosts, since 
reliable, noninvasive diagnostic tests are presently not available; such situations often 
compel the clinician to use drugs in an empiric fashion. However, the suspected fungal 
pathogens are often less susceptible to many antifungal agents including the “broadly-
active” amphotericin B (AmB).4–8 Thus, the choice of appropriate agents for empirical 
antifungal therapy has become a challenge; in the context of recently available, non-
invasive diagnostic tests and newer antifungal drugs, the role of   amphotericin B as a 
drug for empiric therapy has become less clear. This review will provide an overview 
of liposomal amphotericin B (L-AmB) and focus on efficacy studies as well as the 
safety and tolerability of this drug for the empiric treatment of IFIs.
Management of IFIs in the  
immunocompromised host
Multiple factors have contributed to the new epidemiologic trends of IFIs, notably a 
growing number of immunocompromised states (ie, cancer, hematologic stem cell 
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and solid organ transplantation, major surgeries, acquired 
immune deficiency syndrome, the elderly, etc), the advent of 
potent immunosuppressant drugs and their widespread use, 
and the use of antifungal prophylaxis.9–12
In contrast to most bacterial infections, the diagnosis of 
IFIs is challenging. Delay in diagnosis leads to delayed initia-
tion of appropriate antifungal therapy and, hence, increased 
mortality. In this setting, early and definitive diagnosis is 
critical in the management of IFIs. However, clinical pre-
sentation of IFIs is often nonspecific; moreover, signs and 
symptoms could be absent in the early stages of the disease. 
Fever without signs of localized infection is the most com-
mon clinical presentation.13 Fever is of particular concern 
in severely immunosuppressed patients such as those with 
profound and prolonged neutropenia following chemotherapy 
for cancer. Radiographic signs and laboratory tests such as 
galactomannan and 1,3-beta-D-glucan are used as surrogate 
markers for the diagnosis and management of IFIs.14,15
Prompt initiation of appropriate antifungal therapy of 
IFIs is crucial for optimal outcome. Current strategies for 
the management of IFIs include prophylactic, empiric, pre-
emptive, and targeted therapy15,16 (Figure 1). Prophylactic 
strategy includes administration of a narrow- or broad-
spectrum antifungal drug (active against yeasts or yeasts 
and molds) to high-risk patient population before the onset 
of signs/symptoms of infection. Empirical antifungal therapy 
is often initiated when a microbiological diagnosis of IFI is 
unavailable in high-risk presently neutropenic patients pre-
senting with persistent or recurring fevers despite 4–7 days 
of appropriate antibiotic therapy (duration of neutropenia 
expected to be more than 7 days).
Pre-emptive therapy is initiated when suggestive but 
nonspecific radiographic signs are present and/or labora-
tory tests are suggestive of IFIs, without microbiological or 
histopathological confirmation of IFI. Targeted therapy is 
initiated when there is microbiologically and/or histologi-
cally proven IFI.15,16
Antifungal drugs
There are three main classes of systemic antifungal drugs 
available for the treatment of IFIs: polyenes, azoles, and 
echinocandins. Azoles deplete ergosterol and compromise 
fungal cell-wall integrity by dose-dependent inhibition of 
cytochrome-P450-dependent 14α-demethylase.17 Currently 
available systemic azoles include fluconazole, itraconazole, 
voriconazole, and posaconazole. Echinocandins are com-
pounds that disrupt cell-wall synthesis by inhibiting the 
synthesis of 1,3-beta-D-glucan, which is a critical com-
ponent of most fungal cell walls.18 Echinocandins include 
caspofungin, anidulafungin, and micafungin. Azoles and 
echinocandins are relatively safe and well tolerated.18,19
The polyenes include conventional amphotericin B (AmB-D) 
and lipid formulations of amphotericin B (amphotericin B 
lipid complex [ABLC], L-AmB, and amphotericin B colloi-
Without signs or symptoms of infection
Fever plus
– radiologic findings suggestive of fungal infection*
and/or
– POSITIVE serologic test (GM, B-D-glucan and or PCR)
– NO definitive histopathological and/or culture identification of pathogen
Fever plus
– established signs and symptoms of infection (such as persistent fevers)
– unknown source of infection
Fever plus
documented IFI (meet criteria of PROVEN IFI)
High risk for
IFI**
Prophylaxis
Empiric therapy
Pre-emptive therapy
Targeted therapy
Figure 1 Current strategies for the management of IFI in high-risk patients.
Notes:  *High-resolution  computed  tomography  scan  of  the  lungs  showing  new  1  cm  single  or  multiple  nodules  with  or  without  halo  sign,  lobar  consolidation, 
wedge-shaped consolidative infarct; **classic example: patients with proglonged and profound neutropenia after intense chemotherapy for hematologic malignancy.
Abbreviations: GM, serum Galactomannan; IFI, invasive fungal infection; PCR, polymerase chain reaction.
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dal dispersion [ABCD] formulations).20 AmB-D binds with 
sterols, principally ergosterol in the fungal cell   membrane. 
This binding is followed by increased leakage of intracellular 
ions out of the fungal cells resulting in osmotic disruption 
with increased membrane permeability and, ultimately, cell 
death. Polyenes also interfere with membrane-associated oxi-
dative enzyme function, which is also lethal for the cell.20
Lipid formulations of amphotericin B were developed 
to decrease toxicity and improve the tolerability profile of 
AmB-D. Lipid formulations of amphotericin B have differ-
ent structures. ABLC has a ribbon-like structure, ABCD is 
composed of disc-like structures, and L-AmB forms small 
uniform spherical lipid vesicles or liposomes containing 
amphotericin B.21 The three formulations produce tissue 
amphotericin B concentrations ranging from 90% lower than, 
to 500% higher than the serum levels seen with AmB-D. Most 
consistently, reduced concentrations are seen in the kidney, 
thus accounting for the markedly lower nephrotoxicity. The 
doses of lipid forms of amphotericin B are higher than that 
of amphotericin B deoxycholate; such high but equipotent 
doses are better tolerated and there is also a clear reduction 
in the frequency and severity of nephrotoxicity.
Spectrum of activity: amphotericin B
Despite the differences in the structures of lipid formula-
tions and AmB-D, their spectrum of activity is comparable.22 
Amphotericin B is active against clinically relevant yeasts 
such as most Candida spp and Cryptococcus neoformans and 
molds, including most Aspergillus spp and Mucorales. AmB 
is also active against Histoplasma spp, Paracoccidiodes spp, 
Blastomyces spp, and Coccidioides spp.20
Several Candida species such as Candida lusitaniae, 
  Candida guilliermondii, and Candida rugosa may be resis-
tant to AmB.23–25 Also, Trichosporon spp, an infrequent cause 
of catheter-related fungemia, are resistant to AmB.26,27
Non-fumigatus Aspergillus spp, in particular Aspergillus 
terreus, Aspergillus flavus and Aspergillus nidulans, have 
demonstrated clinical resistance to AmB.28–30 Similarly, 
Aspergillus ustus is an uncommon clinical species that 
may have decreased susceptibility to AmB.31–33 However, 
  Aspergillus lentulus, a recently described Aspergillus 
species, has demonstrated variable in vitro susceptibility to 
AmB.34,35 AmB has limited activity against Fusarium spp 
(especially Fusarium solani), although it has better activity 
as compared with other agents such as the older azoles 
(eg, Itraconazole) and echinocandins.8,36,37 Mucorales are 
susceptible to AmB – the drug has been the drug of choice 
for the treatment of mucormycosis; however, clinical response 
has been variable and the overall mortality of patients 
with mucormycosis has remained high, particularly in 
patients with persistent immunosuppression or poor source 
control. A newer azole, posaconazole is active against most 
Mucorales and appears to be promising for the treatment of 
this disease.8,38 Isavuconazole, a more recent broad-spectrum 
azole, available in oral and parenteral forms, is under clinical 
investigation. Scedosporium spp are intrinsically resistant to 
AmB. While Scedosporium apiospermum is susceptible to 
itraconazole, voriconazole, and posaconazole, Scedosporium 
prolificans is considered resistant to all available antifungal 
agents.39,40 Limited data are available to support the optimal 
antifungal therapy against Acremonium spp. Clinically 
relevant species of Acremonium, Alternaria, Cladosporium 
and Exophiala have demonstrated high minimal inhibitory 
concentrations for AmB.41
Safety and tolerance: L-AmB
Conventional amphotericin B (AmB-deoxycholate [AmB-D]) 
was considered the gold standard of antifungal treatment for 
many decades. Infusion-related reactions and dose-dependent 
nephrotoxicity are major limitations of this drug.21 Indeed, 
these side effects are associated with increased morbidity in 
immunocompromised patients.42 Other toxicities reported 
with the use of AmB-D include local thrombophlebitis, nausea 
and vomiting, and anemia. Less frequently, hepatotoxicity 
(ie, transient elevation of transaminase levels and acute liver 
failure) has been associated with the use of AmB-D.42
In general, all lipid formulations of AmB have been 
associated with reduced nephrotoxicity compared with 
  AmB-D.21,43,44 White et al reported a randomized,   double-blind 
multicenter superiority trial in which ABCD (4 mg/kg/d) was 
compared with AmB-D (0.8 mg/kg/d) for the empiric man-
agement of febrile neutropenia.43 Therapeutic response was 
similar (43%–50%), but renal dysfunction was less likely to 
develop and occurred later in ABCD recipients (P , 0.001 
for both parameters). Infusion-related hypoxia and chills were 
more common in ABCD recipients than AmB-D recipients 
(P = 0.013 and P = 0.018, respectively). In clinical practice, 
in view of its frequent infusion-related intolerability, ABCD 
is not favored.
In a randomized, double-blind comparative study, Win-
gard et al evaluated the safety of L-AmB versus ABLC 
in the empirical treatment of febrile neutropenia.45 In this 
study, L-AmB at a dose of 3 or 5 mg/kg/d was associated 
with significantly fewer infusion-related reactions and other 
toxicities (ie, nausea, vomiting) when compared to ABLC at 
a dose of 5 mg/kg/d. There was nonsignificant difference in 
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the rates of hepatotoxicity, hypokalemia, and anemia between 
patients receiving either ABLC or L-AmB. Since the publi-
cation of Wingard et al’s study, it has been widely believed 
that L-AmB is less nephrotoxic than ABLC.   However, in 
a recently published study, Safdar et al conducted a meta-
analysis to evaluate nephrotoxicity associated with ABLC 
and L-AmB.46 After adjusting for heterogeneity across the 
studies included in the meta-analysis, the authors found 
that the nephrotoxicity was similar for ABLC and L-AmB 
in patients receiving either drug as antifungal therapy or 
prophylaxis.
While all three lipid formulations of AmB exhibit reduced 
nephrotoxicity compared with AmB-D, L-AmB appears to be 
the safest in terms of infusion-related reactions. Table 1 sum-
marizes the current US Food and Drug Administration 
(FDA)-approved indications for the use of L-AmB and all 
available antifungal agents.
Empirical therapy: liposomal 
amphotericin B (L-AmB)
The strategy of empirical antifungal therapy has been sys-
temically evaluated only in the setting of antibiotic-refractory 
fever in patients with chemotherapy-induced neutropenia. 
Table 2 summarizes the clinical trials of L-AmB in the 
empiric management of fever in neutropenic patients.
In a randomized trial by Walsh et al, L-AmB was as effec-
tive as AmB-D for the empirical therapy of fever in adult and 
pediatric neutropenic patients.47 In this study, 687 patients 
were randomized to empirical treatment with L-AmB at a dose 
of 3.0 mg/kg/d or AmB-D at 0.6 mg/kg/d.47 Rates of successful 
treatment were similar (50.1% for patients receiving L-AmB 
and 49.4% for those receiving AmB-D.) Rates of survival were 
also similar (93% for L-AmB and 90% for AmB-D). Signifi-
cantly, the use of L-AmB was associated with fewer proven 
breakthrough IFIs (11 patients [3.2%]) compared to patients 
receiving AmB-D (27 patients [7.8%], P = 0.009).
As previously discussed, Wingard et al conducted a 
randomized, double-blind comparative study of L-AmB 
(3–5 mg/kg/d) versus ABLC (5 mg/kg/d) in the empirical 
treatment of febrile neutropenia.45 Among 244 patients 
included, actual response rates were 40% (3 mg/kg/d) and 
42% (5 mg/kg/d) for L-AmB, and 33% for ABLC. While 
the primary endpoint in this study was the incidence of 
infusion-related reactions, the authors found no significant 
differences in successful response and survival in both adult 
and pediatric patients.45
With the introduction of new classes of antifungal agents, 
the efficacy of L-AmB for empirical therapy has been com-
pared with that of caspofungin48–50 and voriconazole.51 Many 
prospective, randomized, multicenter comparative trials evalu-
ating echinocandins have been published48,49,51 (Table 2). In 
these studies, efficacy assessment was based on a composite 
endpoint consisting of five criteria: (1) successful treatment of 
any baseline fungal infection, (2) absence of any breakthrough 
fungal infection during therapy or within 7 days after the 
completion of therapy, (3) survival for 7 days after the comple-
tion of therapy, (4) no premature discontinuation of study 
therapy because of drug-related toxicity or lack of efficacy, 
Table 1 US Food and Drug Administration-approved indication of antifungal agents for the management of IFIs
Indication Echinocandins Newer azoles Polyenes
CAS MICA ANID VOR POS AmB-D ABLC ABCD L-AmB
Empiric treatment of invasive fungal infections YES YES
Prophylaxis of Candida infections YES§ YES*
Prophylaxis of invasive aspergillosis YES*
Target therapy of invasive aspergillosis YES YES YES† YES++ YES‡ YES°
Target therapy of mucormycosis YES† YES++
Salvage treatment of IFIs YES• YES++
Oropharyngeal candidiasis YES YES YES YES YES++ YES°
Invasive candidiasis YES YES YES YES•• YES† YES++ YES°
Notes: *In patients aged 13 years, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem-cell 
transplant recipients with graft versus host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy; §in patients undergoing allogeneic 
hematopoietic stem-cell transplant; •infections with Scedosporium spp and Fusarium spp in patients refractory to or intolerant of other agents. ••in nonneutropenic patients. 
†AmB-D is approved for the treatment of potentially life-threatening fungal infections: aspergillosis; cryptococcosis (torulosis); North American blasmomycosis; systemic 
candidiasis; coccidioidomycosis; histoplasmosis; and zgomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor, and Rhizopus and infections 
due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis; ††ABLC approved for the treatment of invasive fungal infections in patients who are 
refractory to or intolerant of conventional amphotericin B; ‡ABCD is approved for the treatment of invasive aspergillosis in patients who are refractory to or intolerant 
of conventional amphotericin B; °L-AmB (AmBisome) is approved for the treatment of patients with Aspergillus spp, Candida spp, and/or infections due to Cryptococcus spp 
refractory to conventional AmB or in patients with marked renal impairment or when severe toxicity precludes the use of conventional AmB; also approved for the treatment 
of cryptococcal meningitis in human immunodeficiency virus–infected patients and visceral leishmaniasis.
Abbreviations: ABCD, amphotericin B colloidal dispersion; AmB-D, amphotericin B deoxycolate; ABLC, amphotericin B lipid complex; ANID, anidulafungin; CAS, 
caspofungin; IFIs, invasive fungal infections; L-AmB, liposomal amphotericin B; MICA, micafungin; POS, posaconazole; vOR, voriconazole.
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and (5) resolution of fever during neutropenia. Treatment was 
considered successful if all five criteria were met.47
In a randomized, double-blind multicenter trial of 1095 
patients with persistent fever and neutropenia, Walsh et al 
showed that caspofungin was as effective as L-AmB.48 The 
overall success rates were 33.9% for caspofungin and 33.7% 
for L-AmB (95.2% confidence interval: -5.6 to 6.0) caspo-
fungin improved survival (92.6% and 89.2% for caspofungin 
and L-AmB, respectively; P = 0.05) and response rates in 
patients with IFIs (51.9% vs 25.9%; P = 0.04). Breakthrough 
fungal infections were similar in the two groups. Also 
resolution of fever during the period of neutropenia was 
  comparable. Fewer patients in the caspofungin group encoun-
tered nephrotoxicity and there were fewer infusion-related 
events or premature discontinuations of therapy. The authors 
concluded caspofungin to be as effective as L-AmB.
More recently, Maertens et al reported the results of a ran-
domized, double-blind multicenter trial comparing empirical 
therapy with caspofungin versus L-AmB in pediatric patients.49 
In this study, patients were randomized to receive caspofungin 
(70 mg loading dose on day 1 followed by 50 mg/d) or L-AmB 
(3 mg/kg/d). Although the main endpoint of this study was 
safety, clinical efficacy was also evaluated. Overall success 
rates were similar across treatment groups (46.4% and 32% 
for caspofungin and L-AmB, respectively).
Walsh et al conducted a randomized, nonblinded multi-
center trial among febrile neutropenic patients comparing 
empirical antifungal therapy with L-AmB versus vori-
conazole.51 In this study, voriconazole failed to meet the 
prespecified criteria for noninferiority to L-AmB. A total 
of 837 patients (415 assigned to voriconazole and 422 to 
L-AmB) were evaluated for success of treatment. Based 
upon prespecified criteria, voriconazole was inferior to 
L-AmB with overall success rates of 26% with voriconazole 
and 30.6% with L-AmB (95% confidence interval: -10.6 
to 1.6).   Importantly, however, documented breakthrough IFIs 
occurred less frequently among voriconazole recipients – eight 
patients (1.9%) in the voriconazole group versus 21 patients 
(5%) in the L-AmB group (P = 0.02). After stratifying for 
risk, overall success rates were 32% and 30% for high-risk 
patients receiving voriconazole and L-AmB, respectively. The 
authors concluded that voriconazole is a suitable alternative 
to L-AmB for empiric antifungal therapy in patients with 
neutropenia and persistent fever.
Because of its broad spectrum of activity, rarely 
documented resistance, and long track record of clinical 
efficacy, AmB-D has been the standard choice for the 
empirical treatment in patients with persistent fever and 
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neutropenia for many decades. However, antifungal agents 
that have become available over the past 15 years are less 
toxic and are as effective as AmB-D in the empiric treatment 
of IFIs.45,47–51 Indeed, based on the data discussed, L-AmB 
and caspofungin have now been approved by the FDA 
for the empiric antifungal therapy in febrile neutropenic 
patients.52,53
All echinocandins are safe, well tolerated, and have a similar 
spectrum of antifungal activity. However, FDA-approved indi-
cations of these drugs differ.52,53 Caspofungin is approved for 
empirical therapy of febrile neutropenia and for the treatment 
of invasive aspergillosis in patients refractory of or intolerant 
to other approved drugs.53 Micafungin, however, has been 
approved for antifungal prophylaxis in stem-cell transplan-
tation. Limited data suggest that the safety and efficacy of 
caspofungin and micafungin are comparable in the empiric 
treatment of invasive aspergillosis, but micafungin has not 
been licensed for this use.54 Similarly, despite the widespread 
use of voriconazole as empiric therapy and prophylaxis of 
IFIs, voriconazole is not FDA approved for these indications.55 
Posaconazole, based on available data, has been approved for 
the prophylaxis of invasive Aspergillus and Candida infections 
in high-risk, severely immunocompromised adult patients.55
In summary, the three lipid formulations of AmB have 
demonstrated similar efficacy and fewer adverse events 
compared with conventional amphotericin B deoxycholate. 
Amphotericin B colloidal dispersion, in view of its unaccept-
ably high frequency of infusion-related toxicities similar to 
amphotericin B deoxycholate, is no longer favored. L-AmB 
has fewer infusion-related adverse reactions as compared 
with ABLC. Both L-AmB and ABLC appear to have similar 
nephrotoxic potential.
L-AmB has been rigorously evaluated in the empiric treat-
ment of patients with neutropenia and antibiotic-refractory 
fever. The drug appears safe as well as effective. Besides 
neutropenic fever, empiric therapy may be required in some 
nonneutropenic situations as well. For example, allogeneic 
stem-cell recipients with graft versus host disease may require 
empiric antifungal therapy in the setting of undiagnosed, 
nodular pulmonary infiltrates. Although not clinically proven, 
L-AmB may be an appropriate empiric choice in such situ-
ations, particularly in the background of prophylactic use of 
broad-spectrum azoles. During the last decade, many thought 
that amphotericin B-deoxycholate and its lipid forms would 
become obsolete in view of the recently released, less-toxic 
azoles and echinocandins. That has not turned out to be 
so. Despite the fact that amphotericin B is an “old” drug, 
L-AmB plays and will continue to play an important role in 
the empiric antifungal management of patients at high risk 
for invasive fungal infections.
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